Hasil Pencarian  ::  Simpan CSV :: Kembali

"Latar Belakang: Respons patologis kanker payudara terhadap terapi neoadjuvan masih relatif rendah, khususnya di RSCM. Intensitas sTIL dan ekspresi PD-L1 telah diteliti sebagai prediktor respons terapi neoadjuvan. Penelitian ini menilai peran intensitas sTIL dan ekspresi PD-L1 terhadap repons terapi neoadjuvan kanker payudara. Data tersebut dapat dimanfaatkan sebagai data awal di Indonesia, untuk perencanaan terapi pasien kanker payudara yang lebih baik, terlebih dengan sudah tersedianya imunoterapi anti-PD-1/PD-L1.Tujuan: Mengetahui intensitas sTIL dan ekspresi PD-L1 sebagai prediktor respons patologis kanker payudara terhadap terapi neoadjuvan di RSCM.Metode: Penelitian berdesain kohort retrospektif, analitik observasional, pada kasus kanker payudara yang mendapatkan terapi neoadjuvan dan mastektomi di RSCM periode Januari 2014-Desember 2021. Dilakukan total sampling sebanyak 60 kasus. Ekspresi PD-L1 (imunohistokimia, klon 22C3) dan intensitas sTIL (histopatologi) diperiksa pada spesimen biopsi. Dilakukan analisis multivariat regresi linear untuk mendapatkan prediktor independen respons terapi neoadjuvan.Hasil: Didapatkan 60 pasien perempuan, median usia 46 tahun, 91,7% karsinoma invasif no special type. Median intensitas sTIL 10% (1%-70%). Intensitas sTIL rendah (≤10%) pada 58,3% sampel. Ekspresi PD-L1 positif (CPS ≥1) pada 28,3% sampel. Hanya 8,3% sampel mencapai pCR, 90% tergolong RCB kelas II-III. Didapatkan prediktor independen skor RCB: Setiap peningkatan 1% intensitas sTIL, tidak adanya invasi limfovaskular, dan pemberian kemoterapi berbasis taksan diprediksi menurunkan skor RCB sebanyak 0,058 (0,039-0,078), 0,781 (0,241-1,321), dan 0,594 (0,037-1,152). Ekspresi PD-L1 yang positif berhubungan dengan tercapainya pCR-RCB kelas I (p=0,048), tetapi skor CPS bukan merupakan prediktor skor RCB pada analisis multivariat regresi linear.Kesimpulan: Intensitas sTIL merupakan prediktor respons patologis kanker payudara terhadap terapi neoadjuvan di RSCM. Ekspresi PD-L1 berhubungan dengan tercapainya pCR-RCB kelas I, tetapi skor CPS bukan prediktor skor RCB.Kata kunci: PD-L1, programmed-death ligand 1, sTIL, stromal tumour infiltrating lymphocyte, kanker payudara, kemoterapi neoadjuvan, respons patologis......Background: Pathological responses to neoadjuvant therapy were still relatively poor, especially in RSCM. Studies had been done to search for predictors of response such as sTIL intensity and PD-L1 expression, which is known to block sTIL action in killing cancer cells. This research assessed sTIL intensity and PD-L1 expression as predictors of response to neoadjuvant therapy in breast cancer. The preliminary data might be used to better tailored breast cancer patient therapy, considering the availability of anti-PD-1/PD-L1 immunotherapy nowadays.Objective: To assess TIL intensity, PD-L1 expressions, and their roles as pathological predictors of breast cancer reponse to neoadjuvant therapy in RSCM.Method: This was an observational analytic retrospective cohort study on breast cancer patients receiving neoadjuvant therapy and mastectomy in RSCM from January 2014 to December 2021. Total sampling was done. PD-L1 expression (immunohistochemistry, clone 22C3) and sTIL intensity (histopathology) was examined in the biopsy specimen. Linear regression analysis was done to determine the independent predictors of neoadjuvant therapy response (evaluated in the mastectomy specimen with residual cancer burden/RCB score).Results: There were 60 female patients, median age 46 years old. 91,7% had invasive carcinoma of no special type. Median sTIL intensity was 10% (1%-70%). 58,3% patients had low sTIL intensity (≤10%). 28,3% patients had positive PD-L1 expression (CPS ≥1). Only 8,3% patients had pCR, while 90% patients had RCB class II-III. Every 1% increase in sTIL intensity, no lymphovascular invasion, and taxane chemotherapy were predicted to lower RCB score by 0,058, 0,781, dan 0,594, respectively. PD-L1 expression associated with pCR-RCB class I (p=0,048), but CPS score was not a predictor of RCB score in linear regression analysis. Conslusion: sTIL intensity was an independent predictor of breast cancer response to neoadjuvant therapy in RSCM. PD-L1 expression associated with pCR-RCB class I, but CPS score was not a predictor of RCB score. Keywords: PD-L1, programmed death ligand 1, sTIL, stromal tumour infltrating lymphocyte, breast cancer, neoadjuvant therapy, pathological response"

"Latar belakang: Osteosarkoma adalah tumor tulang ganas yang paling banyak terjadi pada anak dan remaja. Kemoterapi neoadjuvan dapat meningkatkan kesintasan 5 tahun hingga 60 – 80% pada pasien osteosarkoma. Baku emas evaluasi respon kemoterapi neoadjuvan adalah histological mapping untuk menilai persentase nekrosis tumor. Volumetri-Magnetic Resonance Imaging (MRI) menggunakan 3D Slicer dapat menilai nekrosis tumor, tumor viabel, dan volume tumor total secara kuantitatif. Tujuan: Menganalisa korelasi volume dan persentase tumor viabel berdasarkan volumetri-MRI dengan nilai persentase tumor viabel berdasarkan pemeriksaan histopatologi pada pasien osteosarkoma pasca kemoterapi neoadjuvan. Metode: Melakukan volumetri tumor pada MRI pasca kemoterapi neoadjuvan dengan menggunakan teknik segmentasi manual dan semiotomatis pada 3D Slicer untuk mendapatkan volume total tumor, area nekrosis, serta tumor viabel. Hasil pengukuran volumetri tumor viabel dan persentase tumor viabel pasca kemoterapi dikorelasikan dengan persentase tumor viabel berdasarkan histopatologi. Analisis dilakukan dengan uji Spearman. Hasil: Pada 31 subyek penelitian, nilai median persentase tumor viabel berdasarkan volumetri-MRI yaitu 65,9% (range 19,7 – 99,5%), sedangkan berdasarkan pemeriksaan histopatologi didapatkan nilai median 53% (range 8 – 100%). Persentase tumor viabel berdasarkan volumetri-MRI tidak berkorelasi signifikan (p>0,05) dengan persentase tumor viabel berdasarkan histopatologi dengan nilai R: 0,333. Kesimpulan: Terdapat kecenderungan berbanding lurus antara persentase tumor viabel berdasarkan volumetri-MRI dan pemeriksaan histopatologi, walaupun tidak terdapat korelasi yang signifikan.......Background: Osteosarcoma is the most common malignant bone tumor in children and adolescents. Neoadjuvant chemotherapy can improve 5-year survival up to 60 - 80% in osteosarcoma patients. The gold standard of neoadjuvant chemotherapy response evaluation is histological mapping to determine the percentage value of tumor necrosis. 3D Slicer volumetry based on Magnetic Resonance Imaging (MRI) can quantitatively assess tumor necrosis, viable tumor, and total tumor volume. Objective: Analyze the correlation between volume and percentage of viable tumors based on MRI-volumetry and histopathological in osteosarcoma patients post neoadjuvant-chemotherapy. Methods: Perform tumor volumetry on MRI post neoadjuvant-chemotherapy using manual and semiautomatic segmentation techniques on 3D Slicer to obtain total tumor volume, necrosis area, and viable tumor. The results of volumetric measurement of viable tumor and the percentage of viable tumor post chemotherapy were correlated with the percentage of viable tumor from histopathological examination. Analysis was performed with Spearman's test. Results: Based on 31 study subjects, the median percentage of viable tumors based on MRI-volumetry was 65.9% (range: 19.7 - 99.5%), while based on histopathology, the median value was 53% (range: 8 - 100%). The percentage of viable tumors based on MRI-volumetry was not significantly correlated (p>0.05) with the percentage of viable tumors based on histopathology with an R value: 0.333. Conclusion: There is a directly proportional trend between the percentage of viable tumors based on MRI-volumetry and histopathological examination, although there was no significant correlation."